Core Viewpoint - Rosen Law Firm is reminding investors who purchased Perrigo Company plc securities between February 27, 2023, and November 4, 2025, of the January 16, 2026, deadline to become a lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Perrigo securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court by January 16, 2026, to serve as lead plaintiff [2] - The lead plaintiff acts on behalf of other class members in directing the litigation [2] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [3] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company and has been ranked highly for securities class action settlements since 2013 [3] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [3] Group 3: Case Allegations - The lawsuit alleges that Perrigo made materially false and misleading statements regarding its infant formula business acquired from Nestlé, which suffered from underinvestment and required substantial capital expenditures [4] - It is claimed that there were significant manufacturing deficiencies in Perrigo's infant formula facility, leading to overstated financial results [4] - The misleading statements about Perrigo's business operations resulted in investor damages when the true details became public [4]

Core Viewpoint - A class action securities lawsuit has been filed against Perrigo Company plc, alleging securities fraud that affected investors between February 27, 2023, and November 4, 2025 [1]. Group 1: Allegations of Fraud - The lawsuit claims that Perrigo's acquisition of the infant formula business from Nestlé was significantly underinvested in maintenance and operational improvements [2]. - It is alleged that Perrigo needed to incur substantial capital and operational expenditures beyond previously stated cost estimates to address issues in the infant formula business [2]. - The complaint points out significant manufacturing deficiencies in the facility related to the infant formula business [2]. - As a result of these issues, Perrigo's financial results, including earnings and cash flow, were reportedly overstated [2]. - The lawsuit asserts that the positive statements made by Perrigo regarding its business and prospects were materially misleading and lacked a reasonable basis [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until January 16, 2026, to request to be appointed as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Perrigo Company plc securities between February 27, 2023, and November 4, 2025, of the January 16, 2026, deadline to become lead plaintiffs in a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Perrigo securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by January 16, 2026 [2]. - The lawsuit alleges that Perrigo made materially false and misleading statements regarding its infant formula business, which suffered from underinvestment and significant manufacturing deficiencies [4]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [3]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company, and has recovered hundreds of millions of dollars for investors [3]. - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [3].

Core Insights - During market turbulence, investors often seek dividend-yielding stocks, which typically have high free cash flows and offer substantial dividends [1] Group 1: Perrigo Company PLC (NYSE:PRGO) - Dividend Yield: 8.32% [6] - JP Morgan analyst Chris Schott maintained a Neutral rating and reduced the price target from $20 to $18 [6] - Canaccord Genuity analyst Susan Anderson kept a Buy rating but cut the price target from $40 to $20 [6] - Recent financial results were mixed, and FY25 adjusted EPS guidance was lowered below estimates [6] Group 2: Bristol-Myers Squibb Co (NYSE:BMY) - Dividend Yield: 4.65% [6] - B of A Securities analyst Tim Anderson upgraded the stock from Neutral to Buy and raised the price target from $51 to $61 [6] - Morgan Stanley analyst Terence Flynn maintained an Underweight rating and increased the price target from $36 to $37 [6] - The company announced an agreement with the U.S. Government to enhance affordability and access to critical medicines [6] Group 3: CVS Health Corp (NYSE:CVS) - Dividend Yield: 3.33% [6] - JP Morgan analyst Lisa Gill maintained an Overweight rating and raised the price target from $93 to $101 [6] - Truist Securities analyst David Macdonald maintained a Buy rating and increased the price target from $95 to $98 [6] - The company raised its FY2025 adjusted EPS and sales guidance [6]

Core Viewpoint - A class action securities lawsuit has been filed against Perrigo Company plc, alleging securities fraud that affected investors between February 27, 2023, and November 4, 2025 [1]. Group 1: Lawsuit Details - The complaint claims that Perrigo made false statements regarding its infant formula business acquired from Nestlé, which suffered from significant underinvestment in maintenance and operational improvements [2]. - It is alleged that Perrigo needed to incur substantial capital and operational expenditures beyond previously stated cost estimates to address issues in the infant formula business [2]. - The lawsuit points out significant manufacturing deficiencies in the facility for the infant formula business, leading to overstated financial results, including earnings and cash flow [2]. - As a result of these issues, the positive statements made by Perrigo about its business operations and prospects were materially misleading [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant time frame have until January 16, 2026, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Perrigo Company plc securities between February 27, 2023, and November 4, 2025, of the January 16, 2026, deadline to become a lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - Investors who purchased Perrigo securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court by January 16, 2026, to serve as lead plaintiff [2] - The lawsuit alleges that Perrigo made materially false and misleading statements regarding its infant formula business, including issues related to underinvestment, necessary capital expenditures, and manufacturing deficiencies [4] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [3] - The firm has been ranked No. 1 for securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions of dollars for investors [3] - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [3]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Perrigo Company plc securities between February 27, 2023, and November 4, 2025, of the upcoming lead plaintiff deadline on January 16, 2026, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Perrigo securities during the specified class period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must file with the court by January 16, 2026 [2]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [3]. - The firm has consistently ranked in the top 4 for securities class action settlements since 2013 and recovered hundreds of millions of dollars for investors, including over $438 million in 2019 [3]. Group 3: Case Allegations - The lawsuit alleges that Perrigo made materially false and misleading statements regarding its infant formula business, including significant underinvestment in maintenance and the need for substantial capital expenditures [4]. - It is claimed that these misstatements led to overstated financial results, including earnings and cash flow, which misled investors about the company's operations and prospects [4].

Group 1: Company Performance - Perrigo Company plc reported third-quarter revenue of $1.04 billion, reflecting a 4.06% decline compared to the same period last year [3] - Operating income for the quarter was $73 million, down from $80 million a year earlier [3] - Despite soft over-the-counter consumption, Perrigo gained dollar, unit, and volume share in five of its seven store-brand categories, indicating strong in-market performance [3] Group 2: Strategic Initiatives - On November 5, Perrigo announced a strategic review of its infant formula business, aiming to shift towards higher-margin branded products [4] - The company is a leading supplier of store-brand baby formula, which has faced challenges due to quality issues at manufacturing facilities [4] Group 3: Market Position and Analyst Ratings - Perrigo is included among the Best Stocks for a Dividend Achievers List, highlighting its position in the market [1] - JPMorgan reduced its price target for Perrigo to $18 from $20 while maintaining a Neutral rating, citing updates to its financial model [2]

Core Viewpoint - A class action securities lawsuit has been filed against Perrigo Company plc, alleging securities fraud that affected investors between February 27, 2023, and November 4, 2025 [1] Group 1: Allegations of the Lawsuit - The lawsuit claims that Perrigo's acquisition of the infant formula business from Nestlé was significantly underinvested in maintenance and operational improvements [2] - It is alleged that Perrigo needed to incur substantial capital and operational expenditures beyond previously stated cost estimates to address issues in the infant formula business [2] - The complaint points out significant manufacturing deficiencies in the facility related to the infant formula business [2] - As a result of these issues, Perrigo's financial results, including earnings and cash flow, were reportedly overstated [2] - The lawsuit asserts that the positive statements made by the defendants regarding Perrigo's business and prospects were materially misleading and lacked a reasonable basis [2] Group 2: Next Steps for Affected Investors - Investors who suffered losses during the specified timeframe have until January 16, 2026, to request to be appointed as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff to share in any potential recovery [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has a strong track record in high-stakes securities litigation [4] - The firm has over 70 employees dedicated to serving clients and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Perrigo Company plc regarding a class action lawsuit alleging that the company made materially false and misleading statements about its infant formula business, which was acquired from Nestlé, leading to overstated financial results [1]. Group 1: Allegations - The complaint alleges that the infant formula business suffered from significant underinvestment in maintenance, operational improvements, and repairs [1] - Perrigo needed to make substantial capital and operational expenditures beyond the company's stated cost estimates to remediate the infant formula business [1] - There were significant manufacturing deficiencies in the facility for the company's infant formula business [1] - As a result of these issues, the company's financial results, including earnings and cash flow, were overstated [1] - Defendants' positive statements about the company's business, operations, and prospects were materially misleading and lacked a reasonable basis [1] Group 2: Class Action Details - The class period for the lawsuit is from February 27, 2023, to November 4, 2025 [1] - Shareholders are encouraged to register for the class action by January 16, 2026, to potentially be appointed as lead plaintiff [2] - Once registered, shareholders will be enrolled in a portfolio monitoring software for status updates throughout the case [2]